Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Johnson & Johnson Reports Worldwide Sales Increase of 1.3% in Fiscal 2022 - Happi
Company News, Financial News

Johnson & Johnson Reports Worldwide Sales Increase of 1.3% in Fiscal 2022

Neutrogena was among the primary drivers for worldwide Consumer Health sales.

 
Johnson & Johnson saw a worldwide increase of 1.3% in sales for fiscal year 2022, or $94.9 billion, the company reported on its official website.
 
Excluding acquisitions/divestitures on an operational basis, the worldwide increase was 6.2%.
 
Diluted earnings per share was $6.73 a decrease of 13.8%. Adjusted diluted earnings per share were $10.15, an increase of 3.6%. 
 
Worldwide Consumer Health sales were $15.0 billion, a 0.5% decrease, but saw an operational increase of 3.6%. Neutrogena, OB, Imodium, Tylenol, Sudafed and Motrin were primary drivers. 
 
“Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, CEO, J&J. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”
 

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters